KR20080077652A - 로 키나제-매개 질환 및 증상 치료용 (인다졸-5-일)피라진및 (1,3-디하이드로인돌-2-온)피라진 - Google Patents

로 키나제-매개 질환 및 증상 치료용 (인다졸-5-일)피라진및 (1,3-디하이드로인돌-2-온)피라진

Info

Publication number
KR20080077652A
KR20080077652A KR1020087015628A KR20087015628A KR20080077652A KR 20080077652 A KR20080077652 A KR 20080077652A KR 1020087015628 A KR1020087015628 A KR 1020087015628A KR 20087015628 A KR20087015628 A KR 20087015628A KR 20080077652 A KR20080077652 A KR 20080077652A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
independently
membered ring
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087015628A
Other languages
English (en)
Korean (ko)
Inventor
마크 알. 헬버그
나잠 에이. 샤리프
제시 에이. 메이
앤드류 루신코
홤그-흐싱 첸
Original Assignee
알콘 리서치, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알콘 리서치, 리미티드 filed Critical 알콘 리서치, 리미티드
Publication of KR20080077652A publication Critical patent/KR20080077652A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020087015628A 2005-12-22 2006-12-19 로 키나제-매개 질환 및 증상 치료용 (인다졸-5-일)피라진및 (1,3-디하이드로인돌-2-온)피라진 Ceased KR20080077652A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75313605P 2005-12-22 2005-12-22
US60/753,136 2005-12-22

Publications (1)

Publication Number Publication Date
KR20080077652A true KR20080077652A (ko) 2008-08-25

Family

ID=37963712

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087015628A Ceased KR20080077652A (ko) 2005-12-22 2006-12-19 로 키나제-매개 질환 및 증상 치료용 (인다졸-5-일)피라진및 (1,3-디하이드로인돌-2-온)피라진

Country Status (14)

Country Link
US (1) US7655662B2 (cg-RX-API-DMAC10.html)
EP (1) EP1962853A1 (cg-RX-API-DMAC10.html)
JP (1) JP2009521494A (cg-RX-API-DMAC10.html)
KR (1) KR20080077652A (cg-RX-API-DMAC10.html)
CN (1) CN101340912A (cg-RX-API-DMAC10.html)
AR (1) AR058618A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0620463A2 (cg-RX-API-DMAC10.html)
CA (1) CA2629342A1 (cg-RX-API-DMAC10.html)
MX (1) MX2008008328A (cg-RX-API-DMAC10.html)
RU (1) RU2008130111A (cg-RX-API-DMAC10.html)
TW (1) TW200733964A (cg-RX-API-DMAC10.html)
UY (1) UY30058A1 (cg-RX-API-DMAC10.html)
WO (1) WO2007076360A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200804497B (cg-RX-API-DMAC10.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2580108T3 (es) * 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
US20070135499A1 (en) * 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
EP2299820A4 (en) * 2008-06-18 2012-11-14 Inspire Pharmaceuticals Inc OPHTHALMOLOGICAL FORMULATION OF RHO KINASE INHIBITOR COMPOUND
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
JP5739448B2 (ja) 2009-12-21 2015-06-24 アレイ バイオファーマ、インコーポレイテッド cFMS阻害剤としての置換N−(1H−インダゾール−4−イル)イミダゾ[1,2−a]ピリジン−3−カルボキサミド化合物
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼ阻害剤として有用な化合物
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013529643A (ja) 2010-06-23 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用なピロロピラジン誘導体
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014KN00943A (cg-RX-API-DMAC10.html) 2011-09-30 2015-08-21 Vertex Pharma
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
US9328200B2 (en) * 2013-07-17 2016-05-03 Ultrasci Discovery Llp Branched polymeric quaternary ammonium compounds and their uses
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2017086941A1 (en) 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021247690A1 (en) * 2020-06-03 2021-12-09 Glaukos Corporation Rho kinase inhibitor releasing implants and related methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492903A1 (en) * 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
JP3719609B2 (ja) * 1995-12-21 2005-11-24 アルコン ラボラトリーズ,インコーポレイテッド 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
PT956865E (pt) * 1996-08-12 2007-07-30 Mitsubishi Pharma Corp Medicamentos compreendendo inibidores da rho cinase.
CA2214841A1 (en) 1997-10-31 1999-04-30 Lisa Mckerracher Rho antagonists and their use to block inhibition of neurite outgrowth
KR100616466B1 (ko) * 1998-08-17 2006-08-29 센주 세이야꾸 가부시키가이샤 녹내장 예방/치료제
AU4144400A (en) * 1999-04-27 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
JP3430254B2 (ja) 2000-03-13 2003-07-28 独立行政法人産業技術総合研究所 β−ジケトナートを有する金属錯体及びその製法、光電変換素子並びに、光化学電池
ES2266171T3 (es) 2000-03-16 2007-03-01 Mitsubishi Pharma Corporation Compuestos de amida y su uso.
JP4776138B2 (ja) * 2000-03-31 2011-09-21 田辺三菱製薬株式会社 腎臓疾患予防・治療剤
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1465900B1 (en) 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003281623B8 (en) 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
CA2502583A1 (en) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same
WO2004084824A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
EP1644365A2 (en) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
US7390907B2 (en) * 2003-09-30 2008-06-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1830853B1 (en) * 2004-12-27 2011-08-10 Novartis AG Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases

Also Published As

Publication number Publication date
CN101340912A (zh) 2009-01-07
RU2008130111A (ru) 2010-01-27
MX2008008328A (es) 2008-09-15
TW200733964A (en) 2007-09-16
EP1962853A1 (en) 2008-09-03
US7655662B2 (en) 2010-02-02
WO2007076360A1 (en) 2007-07-05
CA2629342A1 (en) 2007-07-05
US20070149548A1 (en) 2007-06-28
JP2009521494A (ja) 2009-06-04
AR058618A1 (es) 2008-02-13
BRPI0620463A2 (pt) 2011-11-16
WO2007076360A8 (en) 2007-12-06
UY30058A1 (es) 2007-03-30
ZA200804497B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
US7655662B2 (en) (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure
US7820670B2 (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
KR100994173B1 (ko) 녹내장 및 다른 로 키나아제-매개 질환 치료용아미노피라진 유사체
US12472263B2 (en) Ophthalmic formulation
ES2374336T3 (es) Agente profiláctico o terapéutico para una enfermedad ocular posterior que comprende un agonista selectivo no ergótico del receptor d2 como principio activo.
TWI643619B (zh) 一種用於預防或治療青光眼或高眼壓症、或降低眼壓之醫藥組合物及其用途
US20070142376A1 (en) Control of intraocular pressure using alk5 modulation agents
EA001752B1 (ru) Терапевтическое лечение глазных заболеваний, связанных с фактором роста сосудистого эндотелия
CN100353942C (zh) 用于视网膜神经疾病的含有烷基醚衍生物或其盐的预防剂/治疗剂
KR20200044873A (ko) 안구 제약학적 조성물
US9861593B2 (en) Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
JP4175801B2 (ja) 消炎鎮痛点眼剤
AU2011298430A1 (en) Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
JP2003520245A5 (cg-RX-API-DMAC10.html)
US7867999B1 (en) Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
EP3320904B1 (en) Preventative and/or therapeutic agent containing pyridyl aminoacetic acid compound for treating a disease involving a greatly elevated intraocular pressure
AU2006330599B2 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
JPH06102664B2 (ja) 局所的に有効なカルボニツクアンヒドラーゼ阻害剤としての5―カルバモイルチエノ〔2,3―b〕チオフエン―2―スルホンアミド類及び製造方法
US20160008333A1 (en) Prophylactic or therapeutic agent for posterior ocular disease containing tetrahydropyranylaminocyclopentylcarbonyltetrahydropyridopyridine derivative as effective ingredient
CN115397423A (zh) 用于治疗mps1的组合疗法
KR20070121791A (ko) 각결막 장애 치료제
CN106456641A (zh) 眼后段疾病的预防或治疗剂
HK1232476A1 (zh) 眼後段疾病的预防或治疗剂
TW201605451A (zh) 老年性黃斑部病變之預防或治療劑
JP2004189735A (ja) Limキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080627

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100204

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110920

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120530

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110920

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I